Pediatric non-alcoholic fatty liver disease: New insights and future directions

World Journal of Hepatology

Volumn 6, Issue 4, 2014, Pages 217-225

  Marzuillo, Pierluigi ^a   Giudice, Emanuele Miragliadel ^a   Santoro, Nicola ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fructose; Glucokinase regulatory protein; Insulin resistance; Non alcoholic fatty liver disease; Obesity; PNPLA3

Indexed keywords

EID: 84901234098     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i4.217     Document Type: Short Survey

References (76)

1. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics [PMID: 17015527] 2006; 118: 1388-1393
2. Aly FZ, Kleiner DE. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol [PMID: 21654360 DOI: 10.1097/PAP.0b013e318220f59b] 2011; 18: 294-300
3. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol [PMID: 20195271 DOI: 10.1038/nrgastro.2010.21] 2010; 7: 195-203
4. Day CP. Non-alcoholic fatty liver disease: a massive problem. Clin Med [PMID: 21526706] 2011; 11: 176-178
5. Nobili V, Reale A, Alisi A, Morino G, Trenta I, Pisani M, Marcellini M, Raucci U. Elevated serum ALT in children presenting to the emergency unit: Relationship with NAFLD. Dig Liver Dis [PMID: 19362523 DOI: 10.1016/j.dld.2009.02.048] 2009; 41: 749-752
6. Rodríguez G, Gallego S, Breidenassel C, Moreno LA, Gottrand F. Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents? Nutr Hosp 2010; 25: 712-717 [PMID: 21336425]
7. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, Kusano Y. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci [PMID: 7555456] 1995; 40: 2002-2009
8. Pacifico L, Poggiogalle E, Cantisani V, Menichini G, Ricci P, Ferraro F, Chiesa C. Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World J Hepatol [PMID: 21161009 DOI: 10.4254/wjh.v2.i7.275] 2010; 2: 275-288
9. Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J Pediatr Gastroenterol Nutr [PMID: 15990637] 2005; 41: 94-98
10. Manco M, Marcellini M, Devito R, Comparcola D, Sartorelli MR, Nobili V. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond) [PMID: 18087267] 2008; 32: 381-387
11. Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr [PMID: 19444112 DOI: 10.1097/ MOP.0b013e32832cb16f] 2009; 21: 529-535
12. Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr 2013; 13: 40 [PMID: 23530957 DOI: 10.1186/1471-2431-13-40]
13. Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther [PMID: 18397387 DOI: 10.1111/ j.1365-2036.2008.03703.x] 2008; 28: 13-24
14. Spiteller G. Linoleic acid peroxidation--the dominant lipid peroxidation process in low density lipoprotein--and its relationship to chronic diseases. Chem Phys Lipids [PMID: 9853364] 1998; 95: 105-162
15. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology [PMID: 15565570] 2004; 40: 1387-1395
16. Poustchi H, George J, Esmaili S, Esna-Ashari F, Ardalan G, Sepanlou SG, Alavian SM. Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PLoS One 2011; 6: e21178 [PMID: 21738618 DOI: 10.1371/journal.pone.0021178]
17. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology [PMID: 19637286 DOI: 10.1002/hep.23119] 2009; 50: 1282-1293
18. Lobanova YS, Scherbakov AM, Shatskaya VA, Evteev VA, Krasil'nikov MA. NF-kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis. Mol Cell Biochem [PMID: 19096761 DOI: 10.1007/s11010-008-9985-0] 2009; 324: 65-71
19. Xu JW, Gong J, Chang XM, Luo JY, Dong L, Jia A, Xu GP. Effects of estradiol on liver estrogen receptor-alpha and its mRNA expression in hepatic fibrosis in rats. World J Gastroenterol [PMID: 14716833] 2004; 10: 250-254
20. Nuutila P, Knuuti MJ, Mäki M, Laine H, Ruotsalainen U, Teräs M, Haaparanta M, Solin O, Yki-Järvinen H. Gender and insulin sensitivity in the heart and in skeletal muscles. Studies using positron emission tomography. Diabetes [PMID: 7813811] 1995; 44: 31-36
21. Donahue RP, Bean JA, Donahue RA, Goldberg RB, Prineas RJ. Insulin response in a triethnic population: effects of sex, ethnic origin, and body fat. Miami Community Health Study. Diabetes Care [PMID: 9353606] 1997; 20: 1670-1676
22. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond) [PMID: 18332882 DOI: 10.1038/ijo.2008.25] 2008; 32: 949-958
23. Camporez JP, Jornayvaz FR, Lee HY, Kanda S, Guigni BA, Kahn M, Samuel VT, Carvalho CR, Petersen KF, Jurczak MJ, Shulman GI. Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance. Endocrinology [PMID: 23364948 DOI: 10.1210/en.2012-1989] 2013; 154: 1021-1028
24. Graham RC, Burke A, Stettler N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J Pediatr Gastroenterol Nutr [PMID: 19644391 DOI: 10.1097/ MPG.0b013e31819f73b4] 2009; 49: 442-449
25. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest [PMID: 15864352] 2005; 115: 1343-1351
26. Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in nonalcoholic steatohepatitis patients? Clin Nutr 2006; 25: 816-823 [PMID: 16677739]
27. Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, Kawamura M, Ebihara K, Onji M. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition [PMID: 17140767] 2007; 23: 46-52
28. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol [PMID: 22051327 DOI: 10.1016/j.jacc.2011.06.063] 2011; 58: 2047-2067
29. Li Y, Chen D. The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease. J Hepatol 2012; 57: 468-469; author reply 468-469; [PMID: 22433603 DOI: 10.1016/j.jhep.2012.01.028]
30. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) [PMID: 14720121] 2004; 106: 635-643
31. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology [PMID: 17654743] 2007; 46: 1081-1090
32. Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med 2008; 10: 160 [PMID: 18769702]
33. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructosesweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest [PMID: 19381015 DOI: 10.1172/JCI37385] 2009; 119: 1322-1334
34. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut [PMID: 19625277 DOI: 10.1136/gut.2008.171280] 2009; 58: 1538-1544
35. Santoro N, Feldstein AE, Enoksson E, Pierpont B, Kursawe R, Kim G, Caprio S. The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variants. Diabetes Care [PMID: 23275357 DOI: 10.2337/ dc12-1791] 2013; 36: 1353-1360
36. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet [PMID: 18820647 DOI: 10.1038/ng.257] 2008; 40: 1461-1465
37. Santoro N, Kursawe R, D'Adamo E, Dykas DJ, Zhang CK, Bale AE, Calí AM, Narayan D, Shaw MM, Pierpont B, Savoye M, Lartaud D, Eldrich S, Cushman SW, Zhao H, Shulman GI, Caprio S. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology [PMID: 20803499 DOI: 10.1002/hep.23832] 2010; 52: 1281-1290
38. Giudice EM, Grandone A, Cirillo G, Santoro N, Amato A, Brienza C, Savarese P, Marzuillo P, Perrone L. The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One 2011; 6: e27933 [PMID: 22140488 DOI: 10.1371/journal. pone.0027933]
39. Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, Hobbs HH. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA [PMID: 20385813 DOI: 10.1073/pnas.1003585107] 2010; 107: 7892-7897
40. Li JZ, Huang Y, Karaman R, Ivanova PT, Brown HA, Roddy T, Castro-Perez J, Cohen JC, Hobbs HH. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest [PMID: 23023705] 2012; 122: 4130-4144
41. Cohen AM, Teitelbaum A. Effect of glucose, fructose, sucrose and starch on lipgenesis in rats. Life Sci [PMID: 5638917] 1968; 7: 23-29
42. Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem [PMID: 21878620 DOI: 10.1074/jbc.M111.290114] 2011; 286: 37085-37093
43. Lake AC, Sun Y, Li JL, Kim JE, Johnson JW, Li D, Revett T, Shih HH, Liu W, Paulsen JE, Gimeno RE. Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J Lipid Res [PMID: 16150821] 2005; 46: 2477-2487
44. Polson DA, Thompson MP. Adiponutrin mRNA expression in white adipose tissue is rapidly induced by meal-feeding a high-sucrose diet. Biochem Biophys Res Commun [PMID: 12565853] 2003; 301: 261-266
45. Kershaw EE, Hamm JK, Verhagen LA, Peroni O, Katic M, Flier JS. Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes [PMID: 16380488] 2006; 55: 148-157
46. Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem [PMID: 15364929] 2004; 279: 48968-48975
47. Kumari M, Schoiswohl G, Chitraju C, Paar M, Cornaciu I, Rangrez AY, Wongsiriroj N, Nagy HM, Ivanova PT, Scott SA, Knittelfelder O, Rechberger GN, Birner-Gruenberger R, Eder S, Brown HA, Haemmerle G, Oberer M, Lass A, Kershaw EE, Zimmermann R, Zechner R. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab [PMID: 22560221 DOI: 10.1016/j.cmet.2012.04.008] 2012; 15: 691-702
48. Marzuillo P, Grandone A, Perrone L, Del Giudice EM. Weight loss allows the dissection of the interaction between abdominal fat and PNPLA3 (adiponutrin) in the liver damage of obese children. J Hepatol [PMID: 23845393] 2013; 59: 1143-1144
49. Santoro N, Savoye M, Kim G, Marotto K, Shaw MM, Pierpont B, Caprio S. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS One 2012; 7: e37827 [PMID: 22629460 DOI: 10.1371/journal. pone.0037827]
50. Zampino R, Coppola N, Cirillo G, Boemio A, Pisaturo M, Marrone A, Macera M, Sagnelli E, Perrone L, Adinolfi LE, Miraglia del Giudice E. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat [PMID: 23808989 DOI: 10.1111/jvh.12053] 2013; 20: 517-523
51. Dubuquoy C, Burnol AF, Moldes M. PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function? Clin Res Hepatol Gastroenterol 2013; 37: 30-35 [PMID: 22884299 DOI: 10.1016/j.clinre.2012.06.014]
52. Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, Dykas DJ, Bale AE, Giannini C, Pierpont B, Shaw MM, Groop L, Caprio S. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology [PMID: 22105854 DOI: 10.1002/hep.24806] 2012; 55: 781-789
53. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ, Nalls MA, Clark JM, Mitchell BD, Shuldiner AR, Butler JL, Tomas M, Hoffmann U, Hwang SJ, Massaro JM, O'Donnell CJ, Sahani DV, Salomaa V, Schadt EE, Schwartz SM, Siscovick DS, Voight BF, Carr JJ, Feitosa MF, Harris TB, Fox CS, Smith AV, Kao WH, Hirschhorn JN, Borecki IB. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324 [PMID: 21423719]
54. Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, Teranishi H, Mizusawa S, Ueno T, Chayama K, Nakajima A, Nakao K, Sekine A, Hotta K. Genomewide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet [PMID: 23535911 DOI: 10.1007/s00439-013-1294-3] 2013; 132: 783-792
55. Adams LA, White SW, Marsh JA, Lye SJ, Connor KL, Maganga R, Ayonrinde OT, Olynyk JK, Mori TA, Beilin LJ, Palmer LJ, Hamdorf JM, Pennell CE. Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease. Hepatology [PMID: 23213074 DOI: 10.1002/hep.26184] 2013; 57: 590-600
56. Nobili V, Alisi A, Raponi M. Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol [PMID: 20027672] 2009; 15: 6017-6022
57. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology [PMID: 23390127 DOI: 10.1002/hep.26299] 2013; 57: 2525-2531
58. Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol [PMID: 21876630 DOI: 10.3748/wjg.v17.i29.3377] 2011; 17: 3377-3389
59. Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M, Capuano G, Migliaro F. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr [PMID: 14676594] 2004; 38: 48-55
60. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med [PMID: 20427778 DOI: 10.1056/NEJMoa0907929] 2010; 362: 1675-1685
61. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA [PMID: 21521847 DOI: 10.1001/jama.2011.520] 2011; 305: 1659-1668
62. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for nondiabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther [PMID: 15801922] 2005; 21: 871-879
63. Musso G, Gambino R, Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol [PMID: 19915460 DOI: 10.1097/ MOL.0b013e3283347ebb] 2010; 21: 76-83
64. Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, Groen AK, Hoekstra JB, Stroes ES, Nieuwdorp M. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab [PMID: 21812894 DOI: 10.1111/j.1463-1326.2011.01483.x] 2012; 14: 112-120
65. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut [PMID: 11156641] 2001; 48: 206-211
66. Schrezenmeir J, De Vrese M. Probiotics, prebiotics, and synbiotics--approaching a definition. Am J Clin Nutr 2001; 73: 361S-364S [PMID: 11157342]
67. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes [PMID: 18305141 DOI: 10.2337/db07-1403] 2008; 57: 1470-1481
68. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, Meli R. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr [PMID: 19321579 DOI: 10.3945/jn.108.101808] 2009; 139: 905-911
69. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol [PMID: 15942443] 2005; 39: 540-543
70. Masterton GS, Plevris JN, Hayes PC. Review article: omega- fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther [PMID: 20415840 DOI: 10.1111/j.1365-2036.2010.04230.x] 2010; 31: 679-692
71. Huang JS, Barlow SE, Quiros-Tejeira RE, Scheimann A, Skelton J, Suskind D, Tsai P, Uko V, Warolin JP, Xanthakos SA. Childhood obesity for pediatric gastroenterologists. J Pediatr Gastroenterol Nutr [PMID: 23282941] 2013; 56: 99-109
72. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 2011; 10: 49 [PMID: 21477300 DOI: 10.1186/1476-511X-10-49]
73. Fuchs M. Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. J Lipids 2012; 2012: 934396 [PMID: 22187656 DOI: 10.1155/2012/934396]
74. Miura K, Seki E, Ohnishi H, Brenner DA. Role of tolllike receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease. Gastroenterol Res Pract 2010; 2010: 362847 [PMID: 21274430 DOI:10.1155/2010/362847]
75. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med [PMID: 17479101] 2007; 13: 552-559
76. Lee J, Hong SW, Rhee EJ, Lee WY. GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease. Diabetes Metab J [PMID: 22950055 DOI: 10.4093/dmj.2012.36.4.262] 2012; 36: 262-267